133 results about "Autoimmune thyroid disease" patented technology

The present invention relates to diagnostic applications. For autoimmune diseases more particularly, it is demonstrated herein that individuals with SLE, APLA, MCDS and PSS have antibodies that are specific for SR proteins. Thus, in particular aspects the present invention provides methods and compositions for diagnosing autoimmune disease using SR proteins and antibodies to detect the presence of SR protein-specific antibodies in an individual suspected of having autoimmune disease, wherein the presence of such antibodies is indicative of said individual suffering from autoimmune disease.

The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, Th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (MS), rheumatoid arthritis (RA), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis.

Provided herein are novel panels of biomarkers for the diagnosis of autoimmune diseases, and methods and kits for detecting these biomarkers in samples of individuals suspected of having an autoimmune disease. Also provided are methods of monitoring the progression of an autoimmune disease and methods of monitoring the efficacy and side effects of a treatment for an autoimmune disease.

The present invention relates to substituted fused tricyclic compounds of formula (I) or (Ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity. Such conditions include, but not limited to, arthritis, Alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, T-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, T-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or Type I diabetes, complications from diabetes, rheumatoid arthritis, asthma, Crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis. The present disclosure also relates to process for the preparation of such compounds, and to pharmaceutical compositions containing them.

The present invention relates to an agent for the treatment and/or prophylaxis of an autoimmune disease, an agent for the formation of regulatory T cells (T_Reg) in an organism and various methods in which the agents according to the invention are used.

A quantitative method for performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.

The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus and drug-induced lupus erythematosus by measuring cell-based complement activation products in a subject's blood. In particular, the invention describes a diagnostic method employing the measurement of multiple complement activation products, such as C3d and C4d, on the surfaces of red blood cells, white blood cells, and platelets. Kits and automated systems for performing the methods of the invention are also disclosed.

Provided is an auto-immune disease-related microRNA. In particular, provided is the miR-23b generally down-regulated in the partially inflamed tissue, and further provided are members of the miR-23 family capable of inhibiting the occurrence and development of auto-immune disease after the members are introduced, comprising miR-23a, miR-23b and miR-23C. Also provided is the use of the microRNA in the treatment and prevention of auto-immune disease. The expression of miR-23b is regulated by IL-17, and targets the genes of TAB2 and TAB3, etc., in the signal pathway of inflammatory factors; by inhibiting the expression of TAB2 and TAB3, miR-23b can inhibit the occurrence and development of auto-immune disease and significantly relieve the symptoms and development of the disease.

Techniques using electrical stimulation for treating an Autoimmune Disease by means of an implantable pulse generator and at least one electrode. An electrode lead is surgically implanted in a region of the insular cortex to deliver electrical stimulation. The at least one electrode lead and implantable pulse generator contain features that allow the electrical stimulation to be directed to specific volumes of the insular cortex, and ensure that non-therapeutic volumes do not receive electrical stimulation.

The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention avoid the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease.

The invention relates to an oxadiazoles derivative, a preparation method and a medical application thereof, in particular to the oxadiazoles derivative of general formula 1, the preparation method, a drug composition containing the oxadiazoles derivative, and the application thereof in preparing medicines which can prevent and/or cure diseases with an IDO mediated tryptophan metabolic pathway histopathologic characteristic. The diseases comprise cancer, alzheimer disease, autoimmune disease, depression, anxiety disorder, cataract, psychologic obstacle and HIV disease. Each substituent of the general formula (1) is same with the definition in the description.

Disclosed is an isoxazole derivative that inhibits the activity of the Janus kinases (JAKs), the structure thereof as presented in formula I, formula II, formula IX, and formula XI. The substituent groups in the formulas are described in the description. Also disclosed are the pharmaceutical composition of the compound and a related use in medicine preparation.

This invention provides a human hypothyroid peroxid enzyme antibody magnetic separation enzyme immune measurement method, whose steps are the following: to add sample to react with immune; to wash and to join two anti-enzyme indicate reagent and to wash again; to add monophosphatase fenolftaleina substrate solvent; to terminate color forming and to read absorbing value. The advantages in this invention are the following: it uses reformed human hypothyroid peroxid enzyme antigen fold immune magnetism micro ball as fixed phase and uses alkalescence phosphate enzyme as mark enzyme. Through the quantitative measurement of peroxid enzyme antigen of the hypothyroid patient and normal serum and other clinic symptom, it can judge whether the patient has got the self-immune hypothyroid illness.

The invention provides an immune function assessment kit and assessment method for patients with an autoimmune disease. The immune function assessment kit for the patients the autoimmune disease comprises anti-human CD3, CD4, CD8, CD19, CD21, CD24, CD25, CD27, CD28, CD38, CD57, CD127, CD45RA, CXCR3, CXCR5, CCR4, CCR6, CCR7, HLA-DR, PD-1, IgD, and IgM antibodies, and all antibodies referred carry fluorescein labels. The kit can be used for carrying out comprehensive assessment to the function of immune cells of the patients with the autoimmune disease, and usage is convenient and safe.

The present invention is directed to a method for treating autoimmune diseases comprising administering a therapeutically effective amount of a compound of the following formula (I) wherein X, R1, R2, R3, R4, R5 and R6 are as herein defined.

The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.

The invention describes new peptides containing epitopes recognized by CD4+ natural killer T (NKT) cells for increasing activity for use in infectious diseases, autoimmune diseases, immune reaction to administration of allofactors, allergic diseases, therapy of tumors, prevention of graft rejection and prevention of immunization against viral proteins used in gene therapy or gene vaccination.

The present invention is directed to novel products, variants, pharmaceutically acceptable salts and prodrugs thereof, and medical use of such compounds for the treatment and/or management of sepsis, septicemia, septic shock, ocular infection, ocular inflammation, ocular angiogenesis, rheumatoid arthritis (RA), atherosclerosis, inflammatory bowel diseases (IBD), asthma, chronic obstructive pulmonary disease, fever syndromes, cachexia, psoriasis, autoimmune diseases, cardiac diseases, retinoblastoma, cancer and/or any disorder associated with inflammation, immunomodulation and microbial infection.

Gene therapy compositions for the prevention and/or treatment of autoimmune diseases. The present invention relates to vectors, preferably plasmids that comprise specific promoters, that encode insulin-like growth factor I (IGF-I) or a functional biological equivalent thereof, which will be used to prevent or treat Type 1 Diabetes (DT1) and/or other autoimmune diseases. Moreover, the invention comprises the method of preventing or treating DT1 by means of the expression of IGF-I, or a functional biological equivalent thereof, in hepatic cells. IGF-I was capable of interrupting the immune attack against pancreatic β cells, thereby preventing the loss of β cell mass and, consequently, maintaining normal levels of circulating insulin.